Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease.

Published in: The Annals of pharmacotherapy (2021)

Rapid infusion of infliximab biosimilars (including infliximab-abda) and in patients who have switched among originator infliximab and biosimilars is well tolerated. Future studies should assess clinical impact and outcomes of rapid infusion with biosimilars.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
end stage renal disease
loop mediated isothermal amplification
low dose
newly diagnosed
ejection fraction
peritoneal dialysis
type diabetes
patient reported outcomes
skeletal muscle
case control
weight loss
sensitive detection